Pharmacokinetics of Medroxyprogesterone Acetate in Breast Cancer
Author Information
Author(s): P.A. Canney, M. Dowsett, T.J. Priestman
Primary Institution: Wessex Regional Department of Radiotherapy, Royal South Hants Hospital
Hypothesis
Can a loading dose of medroxyprogesterone acetate (MPA) achieve therapeutic serum levels more quickly in patients with advanced breast cancer?
Conclusion
A loading dose regimen of MPA can achieve therapeutic serum levels quickly without increasing toxicity.
Supporting Evidence
- A loading dose of 1,000mg MPA can achieve serum levels above 100 ng/ml within 36 hours.
- Patients treated with the 48-hour loading dose schedule reached therapeutic levels faster than those on the 24-hour schedule.
- No patients developed symptoms attributable to side effects of MPA during the first two weeks.
Takeaway
This study shows that giving a big dose of a medicine called MPA can help patients with breast cancer get better faster without making them sick.
Methodology
Patients with advanced breast cancer received two different loading dose schedules of MPA, and serum levels were measured at various time points.
Limitations
The study had a small sample size and variability in patient responses.
Participant Demographics
All patients had histologically proven breast carcinoma and normal liver function.
Want to read the original?
Access the complete publication on the publisher's website